Enhertu

With ADCs on the rise, drugmakers embrace a new oncology pillar
Pharma Voice
Fri, 06/6/25 - 11:36 am
oncology
ASCO 2025
antibody-drug conjugates
Daiichi Sankyo
AstraZeneca
Enhertu
Daiichi Sankyo struck gold with ‘ADC’ cancer drugs. Its new CEO has to figure out what’s next.
BioPharma Dive
Thu, 06/5/25 - 09:46 am
ASCO 2025
Daiichi Sankyo
antibody-drug conjugates
Hiroyuki Okuzawa
Enhertu
Datroway
At ASCO, Enhertu cements growing role in stomach cancer care
BioPharma Dive
Mon, 06/2/25 - 10:58 am
ASCO 2025
AstraZeneca
Daiichi Sankyo
stomach cancer
Enhertu
AI tool could help doctors ID breast cancers vulnerable to Enhertu
BioPharma Dive
Thu, 05/22/25 - 09:21 pm
diagnostics
Medtech
breast cancer
artificial intelligence
AstraZeneca
Daiichi Sankyo
Enhertu
New data could move Enhertu into early breast cancer
Pharmaphorum
Wed, 05/7/25 - 11:15 am
AstraZeneca
Daiichi Sankyo
Enhertu
clinical trials
early breast cancer
breast cancer
AstraZeneca, Daiichi say Enhertu delivers 'highly statistically significant' efficacy in first-line breast cancer
Fierce Pharma
Mon, 04/21/25 - 11:12 am
AstraZeneca
Daiichi Sankyo
Enhertu
breast cancer
clinical trials
Daiichi Sankyo and AstraZeneca’s Enhertu shows OS improvements in Phase III trial
Clinical Trials Arena
Tue, 03/4/25 - 09:48 am
Daiichi Sankyo
AstraZeneca
Enhertu
clinical trials
gastric cancer
gastroesophageal adenocarcinoma
Enhertu, with new FDA OK, set to supplant chemo in HER2-low breast cancer
BioPharma Dive
Tue, 01/28/25 - 10:40 am
AstraZeneca
Daiichi Sankyo
Enhertu
HER2-low breast cancer
FDA
England's NICE turns down cancer drug Enhertu—again—amid pricing stalemate with AZ, Daiichi Sankyo
Fierce Pharma
Tue, 11/19/24 - 07:14 pm
AstraZeneca
Daiichi Sankyo
Enhertu
UK
NICE
AstraZeneca, Daiichi withdraw lung cancer approval application for Enhertu follow-up and try again
Fierce Biotech
Tue, 11/12/24 - 08:44 pm
AstraZeneca
Daiichi Sankyo
lung cancer
FDA
Dato-DXd
Enhertu
Daiichi Sankyo partners Alteogen on subcutaneous Enhertu
Pharmaphorum
Fri, 11/8/24 - 11:37 am
Daiichi Sankyo
Alteogen
Enhertu
cancer
Daiichi Sankyo launches first DTC ad for Enhertu, representing shift toward patient-centric oncology campaigns
Medical Marketing and Media
Sun, 09/22/24 - 09:46 pm
Daiichi Sankyo
AstraZeneca
breast cancer
metastatic breast cancer
Enhertu
DTC ads
ESMO-2024: Enhertu to eclipse the standard of care in HER2+ breast cancer with brain metastases
Clinical Trials Arena
Tue, 09/17/24 - 11:20 am
ESMO
breast cancer
Daiichi Sankyo
Enhertu
metastatic breast cancer
clinical trials
EU starts review of Enhertu in HER2-ultra-low breast cancer
Pharmaphorum
Mon, 08/19/24 - 09:56 am
EMA
Europe
AstraZeneca
Daiichi Sankyo
breast cancer
Enhertu
After tense standoff, AstraZeneca and Daiichi's Enhertu turned away by NICE on pricing grounds
Fierce Pharma
Mon, 07/29/24 - 10:51 am
AstraZeneca
Daiichi Sankyo
Enhertu
NICE
UK
HER2-low breast cancer
Daiichi Sankyo Wins $47M in ADC Patent Arbitration With Seagen, Pfizer Dispute Looms
BioSpace
Mon, 07/1/24 - 11:14 am
Daiichi Sankyo
Seagen
patents
Enhertu
ASCO: AstraZeneca, Daiichi's Enhertu looks to make history again in HER2-ultralow breast cancer
Fierce Pharma
Sun, 06/2/24 - 02:46 pm
ASCO 2024
AstraZeneca
Daiichi Sankyo
Enhertu
breast cancer
The Enhertu effect: Daiichi’s plan to build on the success of its crown jewel
Pharma Voice
Fri, 05/10/24 - 11:12 am
Daiichi Sankyo
Enhertu
oncology
Merck
AstraZeneca and Daiichi Sankyo’s Enhertu shows promise in breast cancer trial
Clinical Trials Arena
Mon, 04/29/24 - 11:12 am
AstraZeneca
Daiichi Sankyo
Enhertu
breast cancer
HER2-low breast cancer
FDA grants accelerated approval to Enhertu for metastatic HER2-positive cancers
Investing.com
Sun, 04/7/24 - 04:45 pm
AstraZeneca
Daiichi Sankyo
FDA
Enhertu
solid tumors

Pages